{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:41:05Z","timestamp":1790516465321,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00138","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T16:29:31Z","timestamp":1581092971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the Fc\u03b3RIIB Receptor"],"prefix":"10.3389","volume":"11","author":[{"given":"Maria T.","family":"Georgescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Moorehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","article-title":"High-dose factor VIII inhibits factor VIII \u2013 specific memory B cells in hemophilia A with factor VIII inhibitors","volume":"106","author":"Hausl","year":"2005"},{"key":"B2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/jth.12076","article-title":"Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein","volume":"11","author":"Peters","year":"2013","journal-title":"J Thromb Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J Thromb Haemost."},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000462139","article-title":"Immune tolerance for the treatment of factor VIII inhibitors\u2013twenty years' \u201cbonn protocol\u201d","author":"Brackmann","year":"1996","journal-title":"Vox Sang."},{"key":"B7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood.V86.3.983.983","article-title":"Low-dose immune tolerance induction in hemophilia A patients with inhibitors","volume":"86","author":"Mauser-Bunschoten","year":"1995","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1111\/hae.12740","article-title":"Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: lessons from the international immune tolerance study","volume":"21","author":"Rodriguez","year":"2015","journal-title":"Haemophilia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1172\/JCI118558","article-title":"Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A","volume":"97","author":"Gilles","year":"1996","journal-title":"J Clin Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1182\/blood-2003-07-2207","article-title":"In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody","volume":"103","author":"Gilles","year":"2004","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia."},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nri801","article-title":"Regulation of B-cell signal transduction by adaptor proteins","volume":"2","author":"Kurosaki","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cellimm.2015.12.008","article-title":"Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice","volume":"301","author":"Krishnamoorthy","year":"2016","journal-title":"Cell Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1111\/hae.13064","article-title":"Extended half-life factor VIII for immune tolerance induction in haemophilia","volume":"22","author":"Malec","year":"2016","journal-title":"Haemophilia."},{"key":"B18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/hae.13413","article-title":"Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis","volume":"24","author":"Carcao","year":"2018","journal-title":"Haemophilia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/sji.12573","article-title":"Anti-Fc \u03b3 RIIB (CD32) antibodies differentially modulate murine FVIII-specific recall response in vitro","volume":"86","author":"Vollack","year":"2017","journal-title":"Scand J Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1365-2516.2010.02397.x","article-title":"Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb\/c and C57BL\/6 haemophilia A mice","volume":"17","author":"Qadura","year":"2011","journal-title":"Haemophilia."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2011-08-367813","article-title":"Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs","volume":"119","author":"Dumont","year":"2012"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1182\/blood-2012-09-456582","article-title":"The diversity of the immune response to the A2 domain of human factor VIII","volume":"121","author":"Markovitz","year":"2013","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/eji.201142302","article-title":"Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc\u03b3RIIB (CD32B)","volume":"42","author":"Williams","year":"2012","journal-title":"Eur J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"23420","DOI":"10.1074\/jbc.M202485200","article-title":"Convergence of signaling pathways on the activation of ERK in B cells","volume":"277","author":"Jacob","year":"2002","journal-title":"J Biol Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3324\/haematol.2012.063297","article-title":"Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5","volume":"97","author":"Pegon","year":"2012","journal-title":"Haematologica."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2012-01-408245","article-title":"Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity","volume":"120","author":"Gilbert","year":"2012","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2516.2010.02215.x","article-title":"Factor VIII-specific B cell responses in haemophilia A patients with inhibitors","volume":"16","author":"van Helden","year":"2010","journal-title":"Haemophilia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/bloodadvances.2018024497","article-title":"Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization","volume":"2","author":"Kis-Toth","year":"2018","journal-title":"Blood Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12026-008-8078-1","article-title":"Differential roles for the inositol phosphatase SHIP in the regulation of macrophages and lymphocytes","volume":"43","author":"Leung","year":"2009","journal-title":"Immunol Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.4161\/cc.7.23.7103","article-title":"Regulation of lymphocyte fate by Ras\/ERK signals","volume":"7","author":"Yasuda","year":"2008","journal-title":"Cell Cycle."},{"key":"B32","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1038\/ncomms13264","article-title":"Evaluating frequency and quality of pathogen-specific T cells","volume":"7","author":"Anikeeva","year":"2016","journal-title":"Nat Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T16:29:34Z","timestamp":1581092974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2020.00138"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00138","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"article-number":"138"}}